What is BioStable Science & Engineering?
BioStable Science & Engineering operates at the intersection of medical device innovation and cardiovascular surgery. The company specializes in the development and commercialization of HAART Aortic Repair Technologies, which are engineered to simplify the surgical correction of aortic insufficiency and aortic aneurysm. By providing a viable alternative to valve replacement, BioStable addresses a critical clinical need, aiming to improve patient outcomes through less invasive and more standardized repair techniques. Its market position is defined by a commitment to proprietary engineering that bridges the gap between complex surgical requirements and improved long-term patient health.
How much funding has BioStable Science & Engineering raised?
BioStable Science & Engineering has raised a total of $14M across 3 funding rounds:
Series A
$5.5M
Series B
$4.3M
Series C
$4.2M
Series A (2008): $5.5M with participation from Sante Ventures
Series B (2015): $4.3M led by Sante Ventures
Series C (2020): $4.2M supported by Orlando Health Ventures and Rex Health Ventures
Key Investors in BioStable Science & Engineering
Sante Ventures
A specialized investment firm managing over $1 billion in capital, focusing on innovative healthcare, biotech, and medtech sectors to enhance patient outcomes.
Rex Health Ventures
The investment arm of a private, not-for-profit healthcare system based in North Carolina, dedicated to supporting advancements in medical technology.
Orlando Health Ventures
A strategic investment entity focused on fostering innovation within the healthcare ecosystem to improve clinical delivery and patient care.
What's next for BioStable Science & Engineering?
With the recent influx of capital, BioStable Science & Engineering is well-positioned to accelerate its commercialization efforts and expand the reach of its HAART platform. The strategic focus will likely shift toward broader clinical adoption and the refinement of its surgical training programs. As the company moves beyond its current development stage, the emphasis will remain on demonstrating the long-term clinical benefits of valve repair over replacement, potentially setting a new standard of care in the cardiovascular sector. Continued investment from specialized healthcare venture firms suggests a strong outlook for the company's ability to navigate regulatory milestones and achieve sustained market penetration.
See full BioStable Science & Engineering company page
